PD-1; CTLA-4; immune-checkpoint inhibitors; endocrine organs; irAEs

Blank CU, Enk A. Therapeutic use of anti-CTLA-4 antibodies. Int Immunol 2015; 27(1): 3–10. doi: 10.1093/intimm/dxu076. Okazaki T, Honjo T. PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol 2007; 19(7): 813–824. doi: 10.1093/intimm/dxm057 Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711–723. doi: 10.1056/NEJMoa1003466. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26): 2443–2454. doi: 10.1056/NEJMoa1200690. Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 2017; 13(4): 195–207. doi: 10.1038/nrendo.2016.205. Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 2016; 28(4): 278–287. doi: 10.1097/CCO.0000000000000293. Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013; 98(4): 1361–1375. doi: 10.1210/jc.2012-4075. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4): 375–384. doi: 10.1016/S1470-2045(15)70076-8. Ariyasu H, Inaba H, Ota T, et al. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma. In Vivo 2018; 32(2): 345–351. doi: 10.21873/invivo.11244 Trainer H, Hulse P, Higham CE, et al. Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep 2016; 2016. pii: 16-0108 doi: 10.1530/EDM-16-0108 Shiba M, Inaba H, Ariyasu H, et al. A case of fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody. Intern Med 2018; Feb 28. doi: 10.2169/internalmedicine.9518-17. Teló GH, Carvalhal GF, Cauduro CGS, et al. Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma. Ann Oncol 2017; 28(1): 191–192. doi: 10.1093/annonc/mdw447. Win MA, Thein KZ, Qdaisat A, et al. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am J Emerg Med 2017; 35(7): 1039.e5–1039.e7. doi: 10.1016/j.ajem.2017.02.048. Caturegli P, Newschaffer C, Olivi A, et al. Autoimmune hypophysitis. Endocr Rev 2005; 26(5): 599–614. doi: 10.1210/er.2004-0011 Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 2016; 19(1): 82–92. doi: 10.1007/s11102-015-0671-4. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014; 99(11): 4078–4085. doi: 10.1210/jc.2014-2306. Zhao C, Tella SH, Del Rivero J, et al. Anti-PD-L1 Treatment induced central diabetes insipidus. J Clin Endocrinol Metab 2018; 103(2): 365–369. doi: 10.1210/jc.2017-01905. Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series. Am J Pathol 2016; 186(12): 3225–3235. doi: 10.1016/j.ajpath.2016.08.020. Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014; 6(230): 230ra45. doi: 10.1126/scitranslmed.3008002. Akamizu T, Mori T, Nakao K. Pathogenesis of Graves' disease: Molecular analysis of anti-thyrotropin receptor antibodies. Endocr J 1997; 44(5): 633–646. PMID: 9466318 Akamizu T, Amino N. Hashimoto’s Thyroiditis. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, et al. editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2017 Jul 17. PMID: 25905412 Bookshelf ID: NBK285557 Kiyohara Y, Uhara H, Ito Y, et al. Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance. J Dermatol 2018; 45(4): 408–415. doi: 10.1111/1346-8138.14227. Orlov S, Salari F, Kashat L, et al. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab 2015; 100(5): 1738–1741. doi: 10.1210/jc.2014-4560. de Filette J, Jansen Y, Schreuer M, et al. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J Clin Endocrinol Metab 2016; 101(11): 4431–4439. doi: 10.1210/jc.2016-2300 Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014; 21(2): 371–381. doi: 10.1530/ERC-13-0499. Osorio JC, Ni A, Chaft J, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 2017; 28(3): 583–589. doi: 10.1093/annonc/mdw640. Morganstein DL, Lai Z, Spain L, et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol 2017; 86(4): 614–620. doi: 10.1111/cen.13297. Torino F, Corsello S, Salvatori R, et al. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 2016; 28(4): 278–287. doi: 10.1097/CCO.0000000000000293. Kobayashi T, Iwama S, Yasuda Y, et al. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. J Endocr Soc 2018; 2(3): 241–251. doi. 10.1210/js.2017-00432 Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med 2003; 348(26): 2646–2655. DOI: 10.1056/NEJMra021194 Gan EH, Mitchell AL, Plummer R, et al. Tremelimumab-Induced Graves Hyperthyroidism. Eur Thyroid J 2017; 6(3): 167–170. doi: 10.1159/000464285. Brandão Neto RA, de Carvalho JF. Diagnosis and classification of Addison's disease (autoimmune adrenalitis). Autoimmun Rev 2014; 13(4-5): 408–11. doi: 10.1016/j.autrev.2014.01.025. Joshi MN, Whitelaw BC, Palomar MT, et al. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol 2016;85(3):331–339. doi: 10.1111/cen.13063. Paepegaey AC, Lheure C, Ratour C, et al. Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma. J Endocr Soc 2017; 1(6): 646–649. doi: 10.1210/js.2017-00170. Min L, Ibrahim N. Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol 2013; 1(3): e15. doi: 10.1016/S2213-8587(13)70031-7. Bacanovic S, Burger IA, Stolzmann P. Ipilimumab-induced adrenalitis: A possible pitfall in 18F-FDG-PET/CT. Clin Nucl Med 2015; 40(11): e518-519. doi: 10.1097/RLU.0000000000000887. Scott ES, Long GV, Guminski A, et al. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol 2018; 178(2): 175–182. doi: 10.1530/EJE-17-0810. Akamizu T, Sale M, Rich S, et al. Association of autoimmune thyroid disease with microsatellite markers for the thyrotropin receptor gene and CTLA-4 in Japanese patients. Thyroid 2000; 10(10): 851–858. doi: 10.1089/thy.2000.10.851 Bicek A, Zaletel K, Gaberscek S, et al. 49A/G and CT60 polymorphisms of the cytotoxic T-lymphocyte-associated antigen 4 gene associated with autoimmune thyroid disease. Hum Immunol 2009; 70(10): 820–824. doi: 10.1016/j.humimm.2009.06.016. Hayashi M, Kouki T, Takasu N, et al. Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients. Eur J Endocrinol 2008; 158(6): 817–822. doi: 10.1530/EJE-07-0649. Falorni A, Brozzetti A, Perniola R. From genetic predisposition to molecular mechanisms of autoimmune primary adrenal insufficiency. Front Horm Res 2016; 46: 115–132. doi: 10.1159/000443871. Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet 2016; 387(10035): 2331–2339. doi: 10.1016/S0140-6736(16)30582-7. [43]43 Pizarro C, García-Díaz DF, Codner E, et al. PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile. Diabetes Metab Res Rev 2014; 30(8): 761–766. doi: 10.1002/dmrr.2552. Vita R, Guarneri F, Agah R, et al. Autoimmune thyroid disease elicited by NY-ESO-1 vaccination. Thyroid 2014; 24(2): 390–394. doi: 10.1089/thy.2013.0170. Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review. Ann Oncol 2017; 28(10): 2377–2385. doi: 10.1093/annonc/mdx286. Weber JS, Hamid O, Chasalow SD, et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother. 2012; 35(1): 89–97. doi: 10.1097/CJI.0b013e31823aa41c. Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210(9): 1695–1710. doi: 10.1084/jem.20130579. Kari S, Flynn JC, Zulfiqar M, et al. Enhanced autoimmunity associated with induction of tumor immunity in thyroiditis-susceptible mice. Thyroid 2013; 23(12): 1590–1599. doi: 10.1089/thy.2013.0064. Vudattu NK, Waldron-Lynch F, Truman LA, et al. Humanized mice as a model for aberrant responses in human T cell immunotherapy. J Immunol 2014; 193(2): 587–596. doi: 10.4049/jimmunol.1302455. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198(1): 63–69. Kochupurakkal NM, Kruger AJ, Tripathi S, et al. Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS One 2014; 9(2): e89561. doi: 10.1371/journal.pone.0089561 Yamauchi I, Sakane Y, Fukuda Y, et al. Clinical features of nivolumab-induced thyroiditis: A case series study. Thyroid 2017; 27(7): 894–901. doi: 10.1089/thy.2016.0562 Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018: JCO2017776385. doi: 10.1200/JCO.2017.77.6385 Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 2018; 115: 71–74. doi: 10.1016/j.lungcan.2017.11.019. Seidel JA, Otsuka A, Kabashima K. Treating tumors with immune checkpoint inhibitors: Rationale and limitations. Trends Immunother 2017; 1(1): 2–9. doi: 10.24294/ti.v1.i1.20.